PMID- 7981051
OWN - NLM
STAT- MEDLINE
DCOM- 19950103
LR  - 20190515
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 70
IP  - 6
DP  - 1994 Dec
TI  - 5-En-androstene-3 beta,17 beta-diol inhibits the growth of MCF-7 breast cancer 
      cells when oestrogen receptors are blocked by oestradiol.
PG  - 1035-9
AB  - Adrenal androgens show a dual and apparently opposite effect on the growth of 
      oestrogen-responsive breast cancer: they stimulate growth on their own, but 
      counteract the growth-stimulatory effect of oestrogens. Focusing on the 
      inhibitory action we have studied the effects of 5-en-androstene-3 beta,17 
      beta-diol (ADIOL) on the growth of oestrogen-responsive MCF-7 breast cancer cells 
      in the presence of oestrogens (oestradiol and diethylstilboestrol), antiestrogens 
      (tamoxifen) and antiandrogens (hydroxyflutamide). The inhibition of 
      oestrogen-stimulated growth, attained with nanomolar concentrations of ADIOL, was 
      not modified by increasing concentrations of diethylstilboestrol up to 100 nM. 
      This inhibition was counteracted by antiandrogens, which were unable to block the 
      ADIOL stimulatory effect in steroid-free medium. On the other hand, in the 
      presence of tamoxifen ADIOL showed an additive antiproliferative activity also in 
      steroid-free medium, rather than the usual stimulatory effect. These results 
      suggest that ADIOL stimulates breast cancer cell growth via oestrogen receptors, 
      but inhibits oestrogen-stimulated growth via androgen receptors.
FAU - Boccuzzi, G
AU  - Boccuzzi G
AD  - Department of Clinical Pathophysiology, University of Turin, Italy.
FAU - Brignardello, E
AU  - Brignardello E
FAU - Di Monaco, M
AU  - Di Monaco M
FAU - Gatto, V
AU  - Gatto V
FAU - Leonardi, L
AU  - Leonardi L
FAU - Pizzini, A
AU  - Pizzini A
FAU - Gallo, M
AU  - Gallo M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Receptors, Estrogen)
RN  - 08J2K08A3Y (Dihydrotestosterone)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 31D90UKP5Y (hydroxyflutamide)
RN  - 4TI98Z838E (Estradiol)
RN  - 731DCA35BT (Diethylstilbestrol)
RN  - 76W6J0943E (Flutamide)
RN  - 95PS51EMXY (Androstenediol)
SB  - IM
MH  - Androstenediol/*pharmacology
MH  - Breast Neoplasms/*pathology
MH  - Cell Division/drug effects
MH  - Diethylstilbestrol/pharmacology
MH  - Dihydrotestosterone/pharmacology
MH  - Estradiol/*pharmacology
MH  - Flutamide/analogs & derivatives/pharmacology
MH  - Humans
MH  - Receptors, Estrogen/*antagonists & inhibitors
MH  - Tamoxifen/pharmacology
MH  - Tumor Cells, Cultured
PMC - PMC2033679
EDAT- 1994/12/01 00:00
MHDA- 1994/12/01 00:01
CRDT- 1994/12/01 00:00
PHST- 1994/12/01 00:00 [pubmed]
PHST- 1994/12/01 00:01 [medline]
PHST- 1994/12/01 00:00 [entrez]
AID - 10.1038/bjc.1994.444 [doi]
PST - ppublish
SO  - Br J Cancer. 1994 Dec;70(6):1035-9. doi: 10.1038/bjc.1994.444.